Experimental factors that impact CaV1.2 channel pharmacology-Effects of recording temperature, charge carrier, and quantification of drug effects on the step and ramp currents elicited by the "step-step-ramp" voltage protocol.

导出 OA

翻译打印收藏纠错

作者： Ming,Ren ^[1] ; Aaron L,Randolph ^[1] ; Claudia,Alvarez-Baron ^[2] ; Donglin,Guo ^[1] ; Phu N,Tran ^[3] ; Nicolas,Thiebaud ^[1] ; Jiansong,Sheng ^[4] ; Jun,Zhao ^[1] ; Wendy W,Wu ^[5]

作者单位： Division of Applied Regulatory Science, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America. ^[1] Nanion Technologies Inc, Livingston, New Jersey, United States of America. ^[2] Division of Cardiology and Nephrology, Office of Cardiology, Hematology, Endocrinology and Nephrology, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, United States of America. ^[3] Division of Immunology and Hematology Devices, Center for Devices and Radiological Health, US Food and Drug Administration. Silver Spring, Maryland, United States of America. ^[4] Vertex Pharmaceuticals (Europe) Ltd, Abingdon, Oxfordshire, United Kingdom. ^[5] CiPA Lab, Gaithersburg, Maryland, United States of America. ^[6]

主题词钙通道, L型(Calcium Channels, L-Type);温度(Temperature);结果可重复性(Reproducibility of Results);辅药(Excipients);维拉帕米(Verapamil);美沙酮(Methadone)

DOI 10.1371/journal.pone.0276995

PMID 36417390

发布时间 2022-12-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交